Dr. Guohua Yi joined the faculty at the University of Texas Health Science Center at Tyler in September 2019. He completed his Ph.D. studies at Wuhan University, China, majoring in Molecular Virology. He then pursued his postdoctoral training at Rutgers University and at the Langone Medical Center of New York University. He then joined Texas Tech University Health Sciences Center as a junior faculty member. During that time, Dr. Guohua Yi had interests in immunopathogenesis, gene therapy and vaccine development for a variety of devastating viral diseases, such as HIV, Zika, and influenza viruses. Currently, his research focuses on developing an applicable CRISPR-Cas9 in vivo delivery strategy for T cell and other immune cells gene editing, which may result in novel treatments for HIV and cancers. In addition, his lab’s research also includes phage therapy for the treatment of Mycobacterium tuberculosis (Mtb) infection, the role of HIV-driven metabolites in regulating immune responses to Mtb infection, and the development of a universal vaccine for SARS-CoV-2. Dr. Yi’s research has been funded by National Institute of Allergy and Infectious Diseases (NIAID) and National Heart, Lung, and Blood Institute (NHLBI), as well as Common Funds of the National Institutes of Health (NIH). Dr. Yi has published over 20 peer-reviewed journal papers and served as an ad hoc member for several NIH study sections.

Education and Training

Ph.D.: Wuhan University (Molecular virology)
Postdoctoral training: Rutgers University (Virology), New York University (Medical microbiology), Texas Tech University Health Sciences Center (Immunology).

Research Interest

Gene and cell therapy for infectious diseases and cancer treatments using targeted delivery of gene editing system and CAR-T cells;
Vaccine development for infectious diseases, such as HIV, influenza and SARS-CoV-2;
Targeted phage therapy for treating drug-resistant bacterial infections, including Mycobacterium Tuberculosis.

Publication Highlights

Fan Yang, Li Liu, Pierre Fernand Neuenschwander, Steven Idell, Ramakrishna Vankayalapati, Krishan Gopal Jain, Ke Du, Honglong Ji, Guohua Yi. A phage display-derived peptide for the specific binding of SARS-CoV-2. ACS Omega. 7(4), 3203-3211 (2022). DOI: 10.1021/acsomega.1c04873.

Krishan Gopal Jain, Runzhen Zhao, Yang Liu, Xuan Guo, Guohua Yi, Hong-Long Ji. Wnt5a/b-catenin axis is involved in the downregulation of AT2 lineage by PAI-1. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2022 Sep 13. doi: 10.1152/ajplung.00202.2022.

Jue Wang, Usha R. Pendurthi, Guohua Yi, L. Vijaya Mohan Rao, SARS-CoV-2 infection induces the activation of tissue factor-mediated coagulation by activation of acid sphingomyelinase. Blood. 2021 Jun 1; doi: 10.1182/blood.2021010685. (2021).

K Saha, EJ Sontheimer, PJ Brooks, MR Dwinell, CA Gersbach, DR Liu, ...,Guohua Yi, Jiangbing Zhou. (2021). The NIH somatic cell genome editing program, Nature. 592 (7853), 195-204.

Runzhen Zhao, Zhenlei Su, Andrey A Komissarov, Shan-Lu Liu, Guohua Yi, Steven Idell, Michael A Matthay, Hong-Long Ji, Associations of D-Dimer on Admission and Clinical Features of COVID-19 Patients: A Systematic Review, Meta-Analysis, and Meta-Regression. Frontiers in immunology. 12, 1678. (2021).

X Xu, S Petersen, C Rodriguez, Guohua Yi. VISTA facilitates phagocytic clearance of HIV infected CEM-SS T cells. Heliyon. 7 (7), e07496. (2021).

Guohua Yi, Xuequn Xu, Sojan Abraham, Nora Ortega, Premlata Shankar and Manjunath (2017) A DNA vaccine confers protection against Zika virus infection in humanized mice. EBioMedicine. doi:10.1016/j.ebiom.2017.10.006).

Sojan Abraham, Hua Guo, Jang-Gi Choi, Chunting Ye, Nora Ortega, Guohua Yi, Midhun Ben Thomas, Alok Dwivedi, N Manjunath, Premlata (2017) Combination of IL-2 and IL-10 induces oligoclonal human CD4 T cell expansion during xenogeneic and allogeneic GVHD in Humanized mice. Heliyon, 2017 Apr; 3(4): e00276. doi: 10.1016/j.heliyon.2017.e00276.

Guohua Yi, Xiongying Tu, Preeti Bharaj, Hua Guo, Junli Zhang, Premlata Shankar, Manjunath (2015) Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice. Molecular Therapy, 2015 Oct;23(10):1663-70. doi: 10.1038/mt.2015.107. Epub 2015 Jun 10.

Guohua Yi, Jang GiChoi, Preeti Bharaj, Sojan Abraham, Ying Dang, Tal Kafri, Ogechika Alozie, Manjunath Nmanjunath and Premlata Shankar (2014). CCR5 Gene Editing of Resting CD4+ T Cells by Transient ZFN Expression From HIV Envelope Pseudotyped Nonintegrating Lentivirus Confers HIV-1 Resistance in Humanized Mice. (2014) Molecular Therapy Nucleic Acids. 3 (e198). Doi: 10.1038/mtna.2014.52

JG Choi, P Bharaj, S Abraham, H Ma, G Yi, C Ye, Y Dang, N Manjunath, H Wu, and Premlata Shankar (2015). Multiplexing seven miRNA-based shRNAs to suppress HIV replication. Molecular Therapy. 23 (2), 310-320. Doi: 10.1038/mt.2014.205